XATRAL Tablet Prolonged Release 10 Milligram

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

지금 구매하세요

제품 특성 요약 제품 특성 요약 (SPC)
02-05-2024

유효 성분:

ALFUZOSIN HYDROCHLORIDE

제공처:

PCO Manufacturing

복용량:

10 Milligram

약제 형태:

Tablet Prolonged Release

승인 날짜:

2005-02-11

제품 특성 요약

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Xatral 10mg Prolonged Release Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged release tablet contains 10mg alfuzosin hydrochloride.
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged release tablet
_Product imported from Greece, the UK and Italy:_
Round three layer tablet with one white layer between two yellow layers.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of the functional symptoms of benign prostatic hypertrophy.
Adjunctive therapy with urethral catheterisation for Acute Urinary Retention related to BPH.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Xatral 10mg Prolonged Release Tablets should be swallowed whole.
BPH:The recommended dose is one 10mg tablet once daily to be taken after a meal.
AUR: One 10mg tablet daily after a meal to be taken from the first day of catheterisation.
4.3 CONTRAINDICATIONS
○
Hypersensitivity to alfuzosin or any component.
○
History of orthostatic hypotension.
○
Combination with other -blockers.
○
Hepatic insufficiency.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
WARNINGS
As with all alpha
1
-blockers in some subjects, in particular patients receiving antihypertensive medications, postural
hypotension with or without symptoms (dizziness, fatigue, sweating) may develop within a few hours following
administration. In such cases, the patient should lie down until the symptoms have completely disappeared.
These effects are transient and do not usually prevent the continuation of treatment after adjustment of the dose. The
patient should be warned of the possible occurrence of such events.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 1
                                
                                전체 문서 읽기